Filter By Category
Archives
Share on -
BODITRECTINIB
Generic Name: BODITRECTINIB
ABSTRACT -
Boditrectinib is a Small molecule kinase inhibitor. It is generally described as a TRK/ROS1 tyrosine kinase inhibitor candidate.
Verified structural identifier information used for this sheet includes molecular formula C23H24F2N6O, PubChem CID 121395201. For regulatory filing, confirm final salt form, stereochemistry, hydration state, and manufacturer-specific specification before submission.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Use only according to the approved label, clinical protocol, or specialist direction.
- Dose strength, route, frequency, and duration depend on indication, formulation, renal/hepatic status, and concomitant therapy.
- Do not substitute salt forms, investigational forms, or combination products without formal product review.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Rash, diarrhea, nausea, fatigue, edema, fever, or laboratory abnormalities
- Ocular, cardiac, liver, muscle, or skin toxicity may require monitoring depending on target class.
- Serious infections or treatment-related complications may occur in oncology settings.
ALLERGIC REACTIONS -
Hypersensitivity to Boditrectinib or related compounds/products may occur. Symptoms may include:
- Immediate urticaria or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing or breathing difficulty
- Dizziness, collapse, or anaphylaxis
Important: Patients who develop an allergic reaction to Boditrectinib should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Boditrectinib may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- CYP enzyme inhibitors or inducers may alter exposure for many small molecules.
- Transporter interactions may affect absorption, distribution, or elimination.
- Additive pharmacodynamic effects may occur with medicines affecting the same pathway.
- Patients should disclose prescription medicines, over-the-counter medicines, vaccines, herbal products, and supplements.
PREAUTONS–
- Confirm identity, formulation, strength, route, and intended indication before use.
- Review allergy history and prior serious adverse reactions.
- Assess renal/hepatic function and clinically relevant laboratory values when applicable.
- Pregnancy, lactation, pediatric, and geriatric use should follow label or protocol guidance.
WARNINGS –
- This document is for structured API information only and is not a prescribing guide.
- Use only according to approved labeling, clinical-trial protocol, or qualified specialist instruction.
- Stop use and seek urgent medical care for severe allergic reaction, breathing difficulty, collapse, or serious unexpected symptoms.
- Keep out of reach of children.
Share on -
. Developed by